---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-25-000135"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:19:46.552379+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M

## Summary
- Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).
- Net loss $95.2M ($0.77/sh) vs $115.0M loss year ago; non-GAAP net loss $61.1M ($0.49/sh); cash $803.9M.
- FY2025 revenue guidance raised to $880-$890M (+19-20% YoY) from $850-$860M; screening revenue guided $40-$45M (from $25-$30M).
- Non-GAAP gross margin guided 62-63%; FCF burn expected $225-$235M; ex-screening business on track for FCF breakeven in Q4 2025.
- Shield received CMS ADLT status ($1,495/test) and VA network coverage covering 9M lives; launched upgraded Guardant360 Tissue test.

## SEC filing metadata
- accession: 0001576280-25-000135
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000135/0001576280-25-000135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000135/gh-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-25-000135
- JSON: https://secwatch.observer/filing/0001576280-25-000135.json
- Plain text: https://secwatch.observer/filing/0001576280-25-000135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.